Alkermes plc ( (ALKS) ) has released its Q2 earnings. Here is a breakdown of the information Alkermes plc presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Alkermes plc is a global biopharmaceutical company focused on developing innovative medicines in the field of neuroscience, with a portfolio targeting alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder, as well as a pipeline for neurological disorders like narcolepsy.
In its second-quarter 2025 earnings report, Alkermes plc announced revenues of $390.7 million and a GAAP net income of $87.1 million, with diluted GAAP earnings per share of $0.52. The company also highlighted the positive topline results from its Vibrance-1 study, a significant milestone in its narcolepsy treatment development program.
Key financial metrics for the quarter include total proprietary net sales of $307.2 million, with notable growth in products like VIVITROL, ARISTADA, and LYBALVI. Despite a slight decline in total revenues compared to the previous year, the company maintained robust profitability and cash flow, with cash and investments totaling $1.05 billion as of June 30, 2025.
Alkermes reiterated its financial expectations for 2025 and plans to present detailed results from its Vibrance-1 study at the upcoming World Sleep Congress. The company is preparing to initiate a global phase 3 program for its narcolepsy treatment, highlighting its commitment to advancing its pipeline and addressing unmet medical needs.
Looking ahead, Alkermes remains focused on executing its strategic initiatives and advancing its clinical programs, with management expressing confidence in the potential of its orexin 2 receptor agonists to transform narcolepsy treatment.